drug · antibody
briquilimab
Phase 2updated 3mo agoby $JSPR Jasper Therapeutics, Inc.🔗 ChEMBL
Phase 2community read0 votes
Antibody drug with a maximum clinical stage of Phase 2 (across all indications), with 7 investigational indications.
targets
Mast/stem cell growth factor receptor Kit
all catalysts(0)
nothing on the calendar yet
Trials studying briquilimab
- phase2A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials
- phase2Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
- phase2A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines
- phase1A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
News(2)
- Jasper gets a lifeline in merger with immune drugmaker KiraThe acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.biopharma_dive · 28d ago
- Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to MiradorJasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharmaceuticals.fiercebiotech · 28d ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that